uniQure N.V. (QURE): R&D Expense
$140.67M
Year ended 2025-12-31
$133.71M
Trailing 12 months to 2026-03-31
-10.7%
3-year compound annual growth
+2.8%
5-year compound annual growth
+9.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $140.67M | -2.2% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $143.78M | -33.1% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $214.86M | +8.7% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $197.59M | +37.6% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $143.55M | +17.3% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $122.40M | +29.2% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $94.74M | +26.6% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $74.81M | +3.7% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $72.17M | -0.5% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $72.51M | +22.6% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $59.12M | +35.1% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $43.77M | n/a | 2017-03-15, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | $140.67M | -2.2% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.80M | +28.1% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Evofem Biosciences, Inc. (EVFM) | 2024-12-31 | $1.84M | -37.2% |
Compare QURE, IRD, ABUS, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗